NY-HCL-GROUP
HCL, a global conglomerate and UpLink, the open innovation platform of the World Economic Forum, announced today that applications have opened for the Global Freshwater Innovation Challenge. This is the first out of five Challenges of the HCL and UpLink’s Aquapreneur Innovation Initiative, a programme to source innovative solutions to conserve and restore freshwater ecosystems, from ‘aquapreneurs’ (water focused entrepreneurs). The Initiative, launched during the Forum’s Annual Meeting in Davos in May 2022, will create a first-of-its-kind innovation ecosystem for the global freshwater sector. The last date to apply is November 08, 2022. Full details and eligibility criteria can be found at this link. HCL has committed $15 million over five years to support the water focused entrepreneurs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220920005992/en/
Roshni Nadar Malhotra, Chairperson of HCL Technologies said, “An innovation ecosystem can enable water entrepreneurs with resources and mentoring to invest in creating new solutions and improving any existing ones for scale and impact. There are entrepreneurs and start-ups that have the potential to provide contextualized solutions to conserve freshwater and have been trying to create impact in small ways within small ecosystems. Out of these, many struggle to secure financing and lack the operational capacity to scale their solutions. HCL, through its large network and partnership with the World Economic Forum’s UpLink, is keen to ensure that these entrepreneurs are identified and supported.”
The first year’s challenge, called the Global Freshwater Challenge, will focus on:
- Improved decision-making: solutions that fill knowledge gaps, improve data collection, and create transparent and accessible data (i.e., solutions that monitor and forecast water use & demand)
- Water quality restoration: solutions that tackle water quality by monitoring, treating, restoring or protecting it. (i.e. solutions such as solar distillers for water purification)
- Ecosystem resilience: solutions that protect source waters across the value chain and strengthen resilience to climate and weather-related shocks, taking into consideration the most vulnerable areas at risk (i.e. solutions that reduce water evapotranspiration from extreme heat, or ways to absorb and store acute flooding)
Gim Huay Neo, Managing Director of the Centre for Nature and Climate at the World Economic Forum says, “The Aquapreneur Innovation Initiative invites all entrepreneurs to participate to scale and accelerate their solutions and impact. Through this initiative, we seek to enhance freshwater resilience and better protect our water resource. The collaboration with HCL and UpLink will provide a platform for the top innovators to connect with public and private partners, as well as gain access to venture funds, to jointly transform our sustainable management and use of freshwater systems.”
HCL and UpLink are looking for:
- Stage: Impact-oriented start-ups that are at pilot, growth or scale-up phase, with demonstrated success towards scale (i.e., a proven track record with measurable results and impact). Solutions that represent an “idea” or “prototype” phase will not be considered.
- Business Model: Ideally seeking for-profit start-up companies or social enterprises with a sustainable, and ideally hybrid, funding model.
- Scale: Start-ups which demonstrate the potential to scale, particularly for communities most impacted, alongside a vision for achieving long-term financial viability and sustainability.
Selected entrepreneurs will have the opportunity to work closely with industry experts, investors, and ecosystem partners to further develop their innovative solution, to scale and drive further impact.
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies – HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.8 billion with more than 211,000 employees operating across 52 countries.
HCL Technologies, a group company, empowers global enterprises with technology for the next decade, today. As a leading global technology company, it takes pride in its diversity, social responsibility, sustainability and education initiatives. HCL Technologies is also a strategic partner of the World Economic Forum.
About UpLink
UpLink is the open innovation platform of the World Economic Forum, dedicated to unlocking an ‘entrepreneur revolution’ to support positive systemic change for people and planet. Launched at the Forum’s Annual Meeting in Davos in January 2020 in collaboration with Salesforce and Deloitte, UpLink is now a thriving ecosystem of 50,000+ entrepreneurs, investors and experts, who are collaborating around innovation for the UN Sustainable Development Goals.
For further information, visit www.hcl.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005992/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release
Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release
This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
